[go: up one dir, main page]

DK3137168T3 - Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse - Google Patents

Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse Download PDF

Info

Publication number
DK3137168T3
DK3137168T3 DK15785329.2T DK15785329T DK3137168T3 DK 3137168 T3 DK3137168 T3 DK 3137168T3 DK 15785329 T DK15785329 T DK 15785329T DK 3137168 T3 DK3137168 T3 DK 3137168T3
Authority
DK
Denmark
Prior art keywords
phenylpiperidines
substituted
preparation
Prior art date
Application number
DK15785329.2T
Other languages
English (en)
Inventor
Christopher Cioffi
Graham Johnson
Konstantin Petrukhin
Rando Allikmets
Emily Freeman
Ping Chen
Michael Conlon
Lei Zhu
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of DK3137168T3 publication Critical patent/DK3137168T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK15785329.2T 2014-04-30 2015-04-29 Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse DK3137168T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986578P 2014-04-30 2014-04-30
PCT/US2015/028293 WO2015168286A1 (en) 2014-04-30 2015-04-29 Substituted 4-phenylpiperidines, their preparaiton and use

Publications (1)

Publication Number Publication Date
DK3137168T3 true DK3137168T3 (da) 2022-03-21

Family

ID=54354744

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15785329.2T DK3137168T3 (da) 2014-04-30 2015-04-29 Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse

Country Status (14)

Country Link
US (8) US9434727B2 (da)
EP (2) EP4036094A1 (da)
JP (1) JP6676541B2 (da)
KR (1) KR102429220B1 (da)
CN (2) CN111393434B (da)
AU (1) AU2015253232B2 (da)
BR (1) BR112016025356B1 (da)
CA (1) CA2947174C (da)
DK (1) DK3137168T3 (da)
ES (1) ES2909793T3 (da)
MX (1) MX384244B (da)
PH (1) PH12016502147B1 (da)
SG (1) SG11201608943VA (da)
WO (1) WO2015168286A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
AU2015253232B2 (en) * 2014-04-30 2020-10-01 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
GB201604638D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
TWI841532B (zh) * 2017-06-15 2024-05-11 開曼群島商貝利特生物股份有限公司 以稠合雙環吡唑治療代謝疾病之方法
EP3638239A4 (en) 2017-06-15 2021-03-10 Belite Bio, Inc METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH RBP4 USING TRIAZOLOPYRIDINES
US12440486B2 (en) * 2018-08-01 2025-10-14 The Trustees Of Columbia University In The City Of New York RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
CN119454705A (zh) 2019-07-08 2025-02-18 倍亮生物有限责任公司 Rbp4抑制剂的制剂和使用方法
KR102399432B1 (ko) 2020-04-20 2022-05-19 주식회사 엘파니 전도성 고분자 구조체 표면에 코팅된 금속 박막 층을 포함하는, 하이브리드 구조체 및 이의 제조 방법
WO2022139595A1 (en) 2020-12-23 2022-06-30 Xero Limited Transaction data processing systems and methods
CA3238550A1 (en) * 2021-11-23 2023-06-01 Cheng-Chi Irene Wang Tablet formulations of rbp4 inhibitors and methods of use
WO2025108420A1 (zh) * 2023-11-24 2025-05-30 北京双鹤润创科技有限公司 一种降低rbp4的血清浓度的化合物及用途
WO2025195018A1 (zh) * 2024-03-22 2025-09-25 润尔眼科药物（广州）有限公司 一种苯基哌啶化合物及其应用
WO2025195508A1 (zh) * 2024-03-22 2025-09-25 润尔眼科药物（广州）有限公司 一种苯基杂环化合物及其应用

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926606A1 (de) 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
DE4130514A1 (de) 1991-09-13 1993-03-18 Chemie Linz Deutschland Verfahren zur herstellung reiner n,n'-unsymmetrisch substituierter phenylharnstoffe
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5312814A (en) 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5837716A (en) 1995-11-13 1998-11-17 Albany Medical College Analgesic heterocyclic compounds
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP4095676B2 (ja) 1997-03-03 2008-06-04 エーザイ株式会社 注意障害を治療するためのコリンエステラーゼ阻害剤の使用
WO1999037304A1 (en) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
JP2002518368A (ja) 1998-06-17 2002-06-25 デュポン ファーマシューティカルズ カンパニー メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類
WO2000021557A1 (en) 1998-10-09 2000-04-20 Merck & Co., Inc. Delta 6 fatty acid desaturase
EP1146790A4 (en) 1999-01-25 2004-03-17 Smithkline Beecham Corp COMPOUNDS AND METHODS
ATE346152T1 (de) 1999-04-14 2006-12-15 Merck & Co Inc Neuartige menschliche kalium-potentialabhängige kanäle
WO2001024786A1 (en) 1999-05-13 2001-04-12 Shionogi & Co., Ltd. Preventive or therapeutic drugs for diabetes
EP1185508A2 (en) 1999-05-24 2002-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
PL354998A1 (en) 1999-07-28 2004-03-22 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl compounds
US6372793B1 (en) 1999-08-20 2002-04-16 Florida Agricultural & Mechanical University Method for treatment of a neurological disease characterized by impaired neuromodulator function
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP2140868A1 (en) 2000-03-03 2010-01-06 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
WO2001087921A2 (en) 2000-05-16 2001-11-22 Merck & Co., Inc. Gene responsible for stargardt-like dominant macular dystrophy
EP1313477A4 (en) 2000-07-15 2004-03-03 Smithkline Beecham Corp COMPILATIONS AND METHODS
MXPA03009846A (es) 2001-04-27 2004-05-05 Vertex Pharma Derivados de triazol inhibidores de cinasa y usos de los mismos.
CN1229375C (zh) 2001-07-06 2005-11-30 神经研究公司 烟碱型乙酰胆碱受体抑制剂化合物、其制备和应用
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003032914A2 (en) 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
JP2005517008A (ja) 2002-02-05 2005-06-09 イーライ・リリー・アンド・カンパニー Ｐｐａｒモジュレーターとして用いるためのウレアリンカー誘導体
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
IL164004A0 (en) 2002-03-13 2005-12-18 Janssen Pharmaceutica Nv Piperazinyl-,pipertifinyl-and morpholinyl-derivatives as novel inhibitors of histone deacetylase
AU2003228796A1 (en) 2002-05-01 2003-11-17 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1522314B1 (en) 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
JP2005536526A (ja) 2002-07-25 2005-12-02 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロ−ピラゾール類、その製造方法、およびそれを含有する薬学的組成物
AU2003256922A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US7700583B2 (en) * 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
US7501405B2 (en) * 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
EP1633353A1 (en) 2003-05-30 2006-03-15 Merck & Co., Inc. Composition and method for treating macular disorders
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
FR2857363B1 (fr) * 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP1729761A4 (en) 2004-03-05 2008-09-03 Eisai Co Ltd TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
CN1984901B (zh) 2004-05-18 2011-02-09 先灵公司 用作pde4抑制剂的取代的2-喹啉基-*唑
FR2872416B1 (fr) 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
WO2006004201A1 (ja) 2004-07-01 2006-01-12 Eisai R & D Management Co., Ltd. 神経再生促進剤
MX2007001341A (es) 2004-08-02 2007-04-23 Sanol Arznei Schwarz Gmbh Carboxamidas de indolizina y sus derivados aza y diaza.
JP2006077006A (ja) 2004-08-13 2006-03-23 Eisai Co Ltd 加齢に伴う過活動膀胱治療薬
WO2006033734A2 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
JP4639696B2 (ja) 2004-08-31 2011-02-23 Ｊｓｒ株式会社 磁性体複合粒子およびその製造方法
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AU2005286653A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-CoA-desaturase
KR20070074638A (ko) 2004-10-27 2007-07-12 얀센 파마슈티카 엔.브이. 테트라하이드로 피리디닐 피라졸 카나비노이드 모듈레이터
US7432307B2 (en) 2004-11-04 2008-10-07 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
WO2006065480A2 (en) 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
JP2006176503A (ja) 2004-11-26 2006-07-06 Tohoku Univ 脳血管障害を伴うアルツハイマー病治療薬
JP4178281B2 (ja) 2004-12-08 2008-11-12 シリオン セラピューティクス， インコーポレイテッド レチノール関連疾患を処置するための方法、アッセイおよび組成物
CA2587664A1 (en) * 2004-12-21 2006-06-29 Devgen N.V. Compounds with kv4 ion channel activity
GB0503056D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
AU2006218403A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
CA2608194A1 (en) 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
UA81382C2 (en) 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
KR101020351B1 (ko) * 2005-07-29 2011-03-08 에프. 호프만-라 로슈 아게 인돌-3-일-카본일-피페리딘 및 피페라진 유도체
JPWO2007020888A1 (ja) 2005-08-12 2009-02-26 武田薬品工業株式会社 脳・神経細胞保護剤および睡眠障害治療薬
JP2009507791A (ja) 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
US8993763B2 (en) 2005-09-27 2015-03-31 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
WO2007044804A2 (en) 2005-10-11 2007-04-19 Chemocentryx, Inc. Piperidine derivatives and methods of use
DE102005049954A1 (de) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
DK1961744T3 (da) 2005-11-18 2013-07-15 Ono Pharmaceutical Co Forbindelse indeholdende basiske grupper samt anvendelse deraf
WO2007086584A1 (ja) 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
US20070254911A1 (en) 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
EP2007733B1 (en) 2006-04-03 2016-05-25 MSD Italia S.r.l. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
BRPI0712516A2 (pt) 2006-05-18 2016-08-23 Hoffmann La Roche compostos, composições farmacêuticas, antagonista receptor de a2b, método para uso terapêutico e/ou tratamento profilático e uso de antagonista receptor de a2b
ES2377821T3 (es) 2006-10-11 2012-04-02 Amgen Inc. Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos.
KR20090078367A (ko) 2006-12-08 2009-07-17 에프. 호프만-라 로슈 아게 인돌
DE102006060598A1 (de) 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
CN101842100A (zh) 2007-06-21 2010-09-22 诺伊罗纳森特公司 使用异噻唑并嘧啶酮刺激神经发生和抑制神经元变性的方法和组合物
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
WO2009042444A2 (en) 2007-09-27 2009-04-02 Sirion Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2295406B1 (en) 2008-05-30 2014-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20110092267A (ko) 2008-09-10 2011-08-17 칼립시스, 인코포레이티드 질환의 치료를 위한 히스타민 수용체의 아미노피리미딘 억제제
WO2010077915A1 (en) 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Novel compounds useful as cc chemokine receptor ligands
JP6062633B2 (ja) 2009-01-28 2017-01-18 カラ セラピューティクス インコーポレイテッド 二環式ピラゾロ複素環類
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
WO2010101246A1 (ja) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
TW201041868A (en) 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
US20120010186A1 (en) 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2419412A1 (en) 2009-04-13 2012-02-22 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
WO2010119992A1 (en) 2009-04-16 2010-10-21 Takeda Pharmaceutical Company Limited Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
CA2763008A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US8102887B2 (en) 2009-05-26 2012-01-24 Corning Incorporated Edge bonded optical packages
AR076928A1 (es) 2009-05-28 2011-07-20 Otsuka Pharma Co Ltd Derivados de 3h-pirido[4, 3-d]pirimidin-4-ona, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el estres.
WO2011033255A1 (en) 2009-09-16 2011-03-24 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use
WO2011059881A1 (en) 2009-11-12 2011-05-19 The Trustees Of Columbia University In The City Of New York Treatment of ophthalmic conditions with fluorenone derivatives
CA2781888C (en) 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
WO2011116123A1 (en) 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
US8748632B2 (en) 2010-03-19 2014-06-10 Sanford-Burnham Medical Research Institute Positive allosteric modulators of group II mGluRs
US8796470B2 (en) 2010-05-25 2014-08-05 Abbvie Inc. Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators
WO2011156632A2 (en) 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
US20130085131A1 (en) * 2010-07-01 2013-04-04 Amgen Inc. Heterocyclic compounds and their uses
WO2012025164A1 (en) 2010-08-27 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
WO2012125904A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of egfr
WO2012158844A1 (en) 2011-05-17 2012-11-22 Shionogi & Co., Ltd. Heterocyclic compounds
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2013166040A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York S-fta and s-fta analogues capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular degeneration, stargardt disease, and other retinal disease characterized by excessive lipofuscin accumulation
ES2680355T3 (es) 2012-12-22 2018-09-06 Maytronics Ltd. Robot de limpieza de piscinas autónomo
TW201501713A (zh) * 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd 眼炎症性疾病之預防及／或治療劑
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014152013A1 (en) * 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
US20160030422A1 (en) 2013-03-14 2016-02-04 Konstantin Petrukhin Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
AU2015253232B2 (en) 2014-04-30 2020-10-01 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use

Also Published As

Publication number Publication date
CN106794364A (zh) 2017-05-31
US12404277B2 (en) 2025-09-02
KR20160147037A (ko) 2016-12-21
CA2947174C (en) 2023-02-28
CN106794364B (zh) 2019-12-24
EP3137168A4 (en) 2017-12-20
BR112016025356B1 (pt) 2023-04-18
US20160368925A1 (en) 2016-12-22
EP4036094A1 (en) 2022-08-03
HK1232169A1 (en) 2018-01-05
EP3137168B1 (en) 2022-01-05
WO2015168286A1 (en) 2015-11-05
CN111393434A (zh) 2020-07-10
EP3137168A1 (en) 2017-03-08
WO2015168286A8 (en) 2016-11-17
US20190382409A1 (en) 2019-12-19
KR102429220B1 (ko) 2022-08-04
PH12016502147B1 (en) 2022-03-23
US9777010B2 (en) 2017-10-03
US20150315197A1 (en) 2015-11-05
CA2947174A1 (en) 2015-11-05
US11649240B2 (en) 2023-05-16
US9434727B2 (en) 2016-09-06
MX2016014197A (es) 2017-05-03
US10407433B2 (en) 2019-09-10
PH12016502147A1 (en) 2017-01-16
SG11201608943VA (en) 2016-11-29
US10913746B2 (en) 2021-02-09
AU2015253232A1 (en) 2016-11-24
US10072016B2 (en) 2018-09-11
US20180354957A1 (en) 2018-12-13
US20250320218A1 (en) 2025-10-16
BR112016025356A2 (pt) 2017-08-15
US20230312585A1 (en) 2023-10-05
US20210214360A1 (en) 2021-07-15
JP2017514822A (ja) 2017-06-08
US20180030060A1 (en) 2018-02-01
NZ726053A (en) 2023-10-27
CN111393434B (zh) 2022-11-04
JP6676541B2 (ja) 2020-04-08
BR112016025356A8 (pt) 2021-07-06
MX384244B (es) 2025-03-14
ES2909793T3 (es) 2022-05-10
AU2015253232B2 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
NO2023013I1 (no) Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
DK3154594T3 (da) Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed
DK3393510T5 (da) Zikavirusvaccine
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
EP3346929C0 (en) Electrosurgical snare
BR112017018932A2 (pt) etv2 e usos do mesmo
HUE047581T2 (hu) Készítmény
DK3178837T3 (da) Urlc10-afledt peptid og vaccine, der indeholder dette
UA32568S (uk) Крісло-гойдалка
BR302014000807S1 (pt) Configuração aplicada em cadeira
UA26900S (uk) Крісло-гойдалка
UA26899S (uk) Крісло-гойдалка
UA26898S (uk) Крісло-гойдалка
BR302014000083S1 (pt) Configuração aplicada em poltrona
BR302014001291S1 (pt) Configuração em cadeira